Moneycontrol PRO
Check Credit Score
Check Credit Score
HomeNewsBusinessStocks

Orchid Pharma locked at upper circuit on USFDA nod

The company has received ANDA approval from USFDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

May 15, 2019 / 09:37 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Orchid Pharma locked at upper circuit on May 15 on the back of USFDA nod for Risedronate Sodium Tablets.

At 09:24 hrs Orchid Pharma was quoting at Rs 4, up Rs 0.17, or 4.44 percent.

There were pending buy orders of 33,257 shares, with no sellers available.

The company has received ANDA approval from United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

orchid

For more market news, click here

Moneycontrol News
first published: May 15, 2019 09:36 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347